FOLH1 and prostate neoplasm: Notably, EchoBack-CARs also showed robust efficacy when re-engineered to target prostate-specific membrane antigen (PSMA), a clinically relevant but high-risk antigen expressed in both prostate tumors and healthy kidney and intestinal tissues.